COVINGTON, Ky.–(BUSINESS WIRE)–CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization (CRO) announces the acquisition of Clinart, a full-service CRO with nearly 20 years of experience and strong local expertise in the Middle East and Northern Africa (MENA) region.
Clinart provides an extensive array of services, from early to late-stage research as well as product support in accordance with global and regional requirements. Additionally, the Clinart footprint augments CTI’s current reach in the MENA region, with associates in Egypt, Morocco, Tunisia, Lebanon, Saudi Arabia, Kuwait, Jordan, Oman, and United Arab Emirates, enabling CTI to better serve our customers and their global programs.
Alaa Assem, MD, former CEO of Clinart, is now Managing Director, MENA and will be integral to the success of the integration and the growth of CTI in the MENA region in the near and distant future.
“We are excited to have Clinart join CTI to create a stronger and more robust global full-service CRO,” remarked Patrick J. Earley, CTI’s Chief International Business Officer. “This acquisition has been in the works for quite some time, and despite the global crises we’re currently experiencing, we felt passionately about moving this deal forward for the future success of our organization. In fact, this merger will allow both companies to continue and expand the global reach of their important work in COVID-19 research.”
“Joining CTI allows for our clients to have expanded industry leading therapeutic expertise, a broader global footprint, and a greater capacity for innovative solutions,” according to Alaa Assem, MD, MBA, Managing Director, MENA. “Our employees have been key to our success in the region the last two decades, and they will continue to use their local expertise to support CTI’s growth and projects.”
CTI, now in its third decade, is one of the 20 largest CROs in the world, now with associates in more than 60 countries. The company was recently named the #1 CRO in the world for quality at the 2020 CRO Leadership Awards, outperforming nearly 30 other recognized CROs. CTI is currently managing more than 20 active COVID-19 trials for treatment and prevention, in addition to work in regenerative medicine, rare diseases and other therapeutic indications.
The terms of the acquisition were not disclosed.